Legal Representation
Attorney
Anthony P. Venturino
USPTO Deadlines
Next Deadline
2140 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2025-06-10)
Due Date
June 10, 2031
Grace Period Ends
December 10, 2031
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
24 eventsDate | Code | Type | Description | Documents |
---|---|---|---|---|
Jun 10, 2025 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED | Loading... |
Jun 10, 2025 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
Apr 22, 2025 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
Apr 22, 2025 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
Apr 16, 2025 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
Mar 18, 2025 | PBCR | Z | WITHDRAWN FROM PUB - OG REVIEW QUERY | Loading... |
Feb 28, 2025 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
Feb 27, 2025 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
Feb 27, 2025 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
Feb 27, 2025 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
Feb 27, 2025 | GNEA | F | EXAMINERS AMENDMENT E-MAILED | Loading... |
Jan 7, 2025 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
Jan 7, 2025 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
Jan 7, 2025 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
Dec 18, 2024 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
Dec 18, 2024 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
Dec 18, 2024 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
Oct 22, 2024 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
Oct 22, 2024 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
Oct 22, 2024 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
Oct 21, 2024 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
Sep 14, 2024 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
Sep 14, 2024 | MDSC | E | NOTICE OF DESIGN SEARCH CODE E-MAILED | Loading... |
May 13, 2024 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 009
Downloadable electronic publications in the nature of medical guides in the field of ACROMEGALY disease
First Use Anywhere:
Feb 29, 2024
First Use in Commerce:
Feb 29, 2024
Class 035
Promoting public awareness of ACROMEGALY disease
First Use Anywhere:
Feb 29, 2024
First Use in Commerce:
Feb 29, 2024
Class 041
Education services, namely, providing non-downloadable webinars on the topics of ACROMEGALY disease and healthcare
First Use Anywhere:
Feb 29, 2024
First Use in Commerce:
Feb 29, 2024
Class 042
Providing scientific information in the field of medical disorders and their treatment
First Use Anywhere:
Feb 29, 2024
First Use in Commerce:
Feb 29, 2024
Class 044
Providing a website featuring information about health, namely, ACROMEGALY disease, medical care and health care; providing health and educational information about ACROMEGALY disease; Medical services; Providing health information; Providing medical information in the healthcare sector; Human healthcare services, namely, disease management programs; support services for people affected by genetic diseases, namely, providing an internet-based database of patient medical information where patients can inquire about medical issues and procedures from other patients and can relay information about their medical experiences for support and community; Medical information; Information services relating to health care
First Use Anywhere:
Feb 29, 2024
First Use in Commerce:
Feb 29, 2024
Additional Information
Design Mark
The mark consists of the wording "RETHINK" in stylized form in pink, the wording "ACROMEGALY" in stylized form in grey below the wording "RETHINK" and an arrow head pointing right in pink on right side of those wordings.
Color Claim
The color(s) pink and grey is/are claimed as a feature of the mark.
Classification
International Classes
009
035
041
042
044
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"ACROMEGALY"